Dexamethasone reduces death in ventilated patient by one third, but it is not beneficial to those COVID-19 patients who do not need respiratory support.
The initial clinical trial results from the United Kingdom (UK) show dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with COVID-19. For patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth, according to preliminary findings shared with WHO.
The benefit was only seen in patients seriously ill with COVID-19, and was not observed in patients with milder disease.
Dexamethasone reduces death in ventilated patient by one third, but it is not beneficial to those COVID-19 patients who do not need respiratory support.